Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Arnold

Showing results (131-140 of 234) with videos related to

Pageof 24
Sort By:
Clinical Colorectal Cancer|August 23, 2018
Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC TrialGabriel Glockzin, Florian Zeman, Roland S Croner, et al.
Onkologie|June 24, 2009
[Diagnosis and treatment of liver metastases from primary colorectal tumour]Dirk Arnold, Ernst J Rummeny, Thomas Kirchner, et al.
Journal of Cancer Research and Clinical Oncology|March 6, 2021
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trialsStefanie Noepel-Duennebacke, Hendrik Juette, Karsten Schulmann, et al.
Acta Oncologica (Stockholm, Sweden)|September 13, 2013
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II studyAlexander Stein, Dirk Arnold, Peter C Thuss-Patience, et al.
British Journal of Cancer|November 11, 2017
Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trialsKaitlyn K H Goey, Sjoerd G Elias, Axel Hinke, et al.
Onkologie|December 17, 2008
[Treatment of nonresectable liver metastases]Markus Moehler, Karsten Ridwelski, Meinolf Karthaus, et al.
European Journal of Translational Myology|November 18, 2024
Efficacy of electrical stimulation of the zygomaticus muscle in complete facial paralysis: evidence from facial grading and automated image analysisJohannes Krauß, Gabriel Meincke, Maren Geitner, et al.
BMC Cancer|October 15, 2014
Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study resultsRalf Hofheinz, Volker Petersen, Manfred Kindler, et al.
BMC Cancer|August 18, 2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literatureAlexander Stein, Gabriel Glockzin, Andreas Wienke, et al.
Plos One|August 11, 2022
Accessing the stapedius muscle via novel surgical retrofacial approach during cochlear implantation surgery: Intraoperative results on feasibility and safetyOrlando Guntinas-Lichius, Dirk Arnold, Gerd Fabian Volk, et al.
Pageof 24

Showing results (131-140 of 234) with videos related to

Sort By:
Pageof 24
Clinical Colorectal Cancer|August 23, 2018
Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC TrialGabriel Glockzin, Florian Zeman, Roland S Croner, et al.
Onkologie|June 24, 2009
[Diagnosis and treatment of liver metastases from primary colorectal tumour]Dirk Arnold, Ernst J Rummeny, Thomas Kirchner, et al.
Journal of Cancer Research and Clinical Oncology|March 6, 2021
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trialsStefanie Noepel-Duennebacke, Hendrik Juette, Karsten Schulmann, et al.
Acta Oncologica (Stockholm, Sweden)|September 13, 2013
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II studyAlexander Stein, Dirk Arnold, Peter C Thuss-Patience, et al.
British Journal of Cancer|November 11, 2017
Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trialsKaitlyn K H Goey, Sjoerd G Elias, Axel Hinke, et al.
Onkologie|December 17, 2008
[Treatment of nonresectable liver metastases]Markus Moehler, Karsten Ridwelski, Meinolf Karthaus, et al.
European Journal of Translational Myology|November 18, 2024
Efficacy of electrical stimulation of the zygomaticus muscle in complete facial paralysis: evidence from facial grading and automated image analysisJohannes Krauß, Gabriel Meincke, Maren Geitner, et al.
BMC Cancer|October 15, 2014
Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study resultsRalf Hofheinz, Volker Petersen, Manfred Kindler, et al.
BMC Cancer|August 18, 2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literatureAlexander Stein, Gabriel Glockzin, Andreas Wienke, et al.
Plos One|August 11, 2022
Accessing the stapedius muscle via novel surgical retrofacial approach during cochlear implantation surgery: Intraoperative results on feasibility and safetyOrlando Guntinas-Lichius, Dirk Arnold, Gerd Fabian Volk, et al.
Pageof 24